Clinical Cure Rates in Patients With Comorbidities

Consistent clinical cure rates in cSSTI across infection types and in patients with comorbidities^1-5,*
 

ZINFORO^® demonstrated microbiological response and clinical cure rates at TOC (CANVAS 1 and CANVAS 2 integrated analysis).¹

Clinical cure rates by analysis population at the TOC visit¹
 

• ZINFORO^®: 92.7% of patients (n=434/468)
   

• Vancomycin + Aztreonam: 94.4% of patients (n=421/446)

Clinical cure rates (CE population) at the TOC visit¹:

• ZINFORO^®: 91.6% of patients (n=559/610)
   

• Vancomycin + Aztreonam: 92.7% of patients (n=549/592)

CANVAS 1 and CANVAS 2 integrated analysis¹

Adapted from Corey G, et al. 2010.

*There is no experience with ZINFORO® in the treatment of cSSTI in the following patient groups⁶: The immunocompromised, patients with severe sepsis/septic shock, necrotising fasciitis, perirectal abscess and patients with third-degree and extensive burns. There is limited experience in treating patients with diabetic foot infections. Caution is advised when treating such patients.
^†Bacteraemia was present in 4% of the patients when baseline medical characteristics were assessed.¹

CANVAS, CeftAroliNe fosamil versus VAncomycin in Skin and skin structure infection; CE, clinically evaluable; cSSTI, complicated skin and soft tissue infection; ME, microbiologically evaluable; TOC, test of cure.
 

References: